D.A. Davidson & CO. increased its holdings in shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 157,000 shares of the biotechnology company’s stock after acquiring an additional 109,000 shares during the period. D.A. Davidson & CO.’s holdings in Actinium Pharmaceuticals were worth $104,000 as of its most recent SEC filing.
Shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) opened at $0.47 on Tuesday. The company has a market capitalization of $43.03, a price-to-earnings ratio of -1.00 and a beta of 40.77. Actinium Pharmaceuticals Inc has a 12-month low of $0.43 and a 12-month high of $1.68.
A number of research analysts recently weighed in on the company. Maxim Group set a $3.00 price objective on Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 12th. B. Riley assumed coverage on Actinium Pharmaceuticals in a report on Wednesday, December 6th. They set a “buy” rating and a $2.75 price objective on the stock. Finally, Zacks Investment Research raised Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a report on Tuesday, January 9th. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $3.75.
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Want to see what other hedge funds are holding ATNM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.